Skip to main content
SpringerLink
Log in

Role of Atypical Antipsychotics in the Treatment of Generalized Anxiety Disorder

CNS Drugs volume 28, pages 519–533 (2014)Cite this article

Abstract

Evidence-based treatment approaches for generalized anxiety disorder (GAD) comprise psychotherapy, pharmacotherapy, or a combination of the two. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, and, in certain European guidelines, pregabalin, which gained European Commission approval. Although short- and long-term efficacy have been established for these agents in controlled trials, response rates of 60–70 % are insufficient, remission rates are relatively modest, and relapse rates considerable. Moreover, questions increasingly arise regarding tolerability and side-effect profiles. As an alternative, antipsychotics have long been of interest for the treatment of anxiety disorders, but investigation had been tempered by their potential for irreversible side effects. With the improved side-effect profiles of atypical antipsychotics, these agents are increasingly being investigated across Axis I disorders. Atypical antipsychotics such as quetiapine, aripiprazole, olanzapine, and risperidone have been shown to be helpful in addressing a range of anxiety and depressive symptoms in individuals with schizophrenia and schizoaffective disorders, and have since been used in the treatment of a range of mood and anxiety disorders. In this article, we review the efficacy and tolerability of atypical antipsychotics as adjunctive therapy and/or monotherapy for individuals with GAD, a currently off-label indication. The most evidence has accumulated for quetiapine. Findings suggest that approximately 50 % of participants tolerate the side effects, most commonly sedation and fatigue. Among this subset, those who continue treatment demonstrate significant reductions in anxiety when used as adjunctive therapy or monotherapy. The appropriateness of the use of antipsychotics in the treatment of GAD is discussed.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Similar content being viewed by others

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, rev. Washington, DC: American Psychiatric Association; 1987.

  3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.

  4. American Psychiatric Association: Diagnostic and statistical manual of mental disorders, 5th ed. American Psychiatric Association: Washington, DC; 2013.

  5. Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, Smith SM, Saha TD, Huang B. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35(12):1747–59.

    Article  PubMed  Google Scholar 

  6. Kroenke K, Spitzer RL, Williams JBW, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317–25.

    Article  PubMed  Google Scholar 

  7. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16(4):162–71.

    Article  PubMed  Google Scholar 

  8. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med. 2004;351(1):13–22.

    Article  CAS  PubMed  Google Scholar 

  9. Milanak ME, Gros DF, Magruder KM, Brawman-Mintzer O, Frueh BC. Prevalence and features of generalized anxiety disorder in Department of Veteran Affairs primary care settings. Psychiatry Res. 2013;209:173–9.

    Article  PubMed  Google Scholar 

  10. Phillips AC, Batty GD, Gale CR, Deary IJ, Osborn D, MacIntyre K, Carroll D. Generalized anxiety disorder, major depressive disorder, and their comorbidity as predictors of all-cause and cardiovascular mortality: the Vietnam experience study. Psychosom Med. 2009;71(4):395–403.

    Article  CAS  PubMed  Google Scholar 

  11. Brown TA, Barlow DH, Liebowitz MR. The empirical basis of generalized anxiety disorder. Am J Psychiatry. 1994;151(9):1272–80.

    CAS  PubMed  Google Scholar 

  12. Yonkers KA, Bruce SE, Dyck IR, Keller MB. Chronicity, relapse, and illness—course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety. 2003;17(3):173–9.

    Article  PubMed  Google Scholar 

  13. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. Major depression and generalized anxiety disorder: same genes, (partly) different environments? Arch Gen Psychiatry. 1992;49(9):716.

    Article  CAS  PubMed  Google Scholar 

  14. Rodríguez BF, Bruce SE, Pagano ME, Keller MB. Relationships among psychosocial functioning, diagnostic comorbidity, and the recurrence of generalized anxiety disorder, panic disorder, and major depression. J Anxiety Disord. 2005;19(7):752–66.

    Article  PubMed  Google Scholar 

  15. Wittchen H-U, Zhao S, Kessler RC, Eaton WW. DSM-III—R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:355–64.

    Article  CAS  PubMed  Google Scholar 

  16. Fava M, Rankin MA, Wright EC, Alpert JE, Nierenberg AA, Pava J, Rosenbaum JF. Anxiety disorders in major depression. Compr Psychiatry. 2000;41(2):97–102.

    Article  CAS  PubMed  Google Scholar 

  17. Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol. 2000;15(6):319–28.

    Article  CAS  PubMed  Google Scholar 

  18. Kessler RC, DuPont RL, Berglund P, Wittchen H-U. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry. 1999;156(12):1915–23.

    CAS  PubMed  Google Scholar 

  19. DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety. 1996;2(4):167–72.

    Article  CAS  PubMed  Google Scholar 

  20. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999;60:427–35.

    Article  CAS  PubMed  Google Scholar 

  21. Woodman CL, Noyes R, Black DW, Schlosser S, Yagia SJ. A five-year follow-up study of generalized anxiety disorder and panic disorder. J Nerv Men Dis. 1999;187:3–9.

    Article  CAS  Google Scholar 

  22. Wittchen H-U, Kessler RC, Beesdo K, Krause P, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63:24–34.

    PubMed  Google Scholar 

  23. Dilbaz N, Darcin EA. Treatment of generalized anxiety disorders: unmet needs. In: Durbano F, editor. New insights into anxiety disorders. New York: InTech. ISBN:978-953-51-1053-8. http://www.intechopen.com/books/new-insights-into-anxiety-disorders/treatment-of-generalized-anxiety-disorders-unmet-needs.

  24. Newman M, Borkovec T. Cognitive behaviour therapy: a guide for the practising clinician. In: Simos G, editor. Cognitive behavioral therapy for worry and generalized anxiety disorder. New York: Taylor & Francis; 2002. p. 150–72.

    Google Scholar 

  25. Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry. 2001;62:37–45.

    PubMed  Google Scholar 

  26. Hayes SC, Villatte M, Levin M, Hildebrandt M. Open, aware, and active: contextual approaches as an emerging trend in the behavioral and cognitive therapies. Annu Rev Clin Psychol. 2011;7:141–68.

    Article  PubMed  Google Scholar 

  27. Orsillo SM, Roemer L, Barlow DH. Integrating acceptance and mindfulness into existing cognitive-behavioral treatment for GAD: a case study. Cognit Behav Pract. 2003;10(3):222–30.

    Article  Google Scholar 

  28. Roemer L, Orsillo SM. An open trial of an acceptance-based behavior therapy for generalized anxiety disorder. Behav Ther. 2007;38(1):72–85.

    Article  PubMed  Google Scholar 

  29. Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev. 2007;(1):CD001848.

  30. Newman MG, Castonguay LG, Borkovec TD, Fisher AJ, Boswell JF, Szkodny LE, Nordberg SS. A randomized controlled trial of cognitive-behavioral therapy for generalized anxiety disorder with integrated techniques from emotion-focused and interpersonal therapies. J Consult Clin Psychol. 2011;79(2):171–81.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Wells A, Welford M, King P, Papageorgiou C, Wisely J, Mendel E. A pilot randomized trial of metacognitive therapy vs applied relaxation in the treatment of adults with generalized anxiety disorder. Behav Res Ther. 2010;48(5):429–34.

    Article  PubMed  Google Scholar 

  32. Katzman MA. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(2):103–20.

    Article  CAS  PubMed  Google Scholar 

  33. Reinhold JA, Mandos LA, Rickels K, Lohoff FW. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2011;12(16):2457–67.

    Article  CAS  PubMed  Google Scholar 

  34. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Möller HJ. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77–84.

    Article  CAS  PubMed  Google Scholar 

  35. Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011;342:1–11.

    Google Scholar 

  36. Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21(8):864–72.

    Article  CAS  PubMed  Google Scholar 

  37. Katzman MA, Copeland A, Klassen LJ, Chokka P, Brawman-Mintzer O. Pharmacotherapy for generalized anxiety disorder. Psychiatr Ann. 2011;41(2):95–103.

    Article  Google Scholar 

  38. Dell’Osso B, Buoli M, Baldwin DS, Altamura AC. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Human Psychopharmacol Clin Exp. 2010;25(1):17–29.

    Article  Google Scholar 

  39. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV: medications and other biological treatments. Can J Psychiatry. 2001;46:38S–58S.

    PubMed  Google Scholar 

  40. Dobrea C, Buoli M, Arici C, Camuri G, Dell’Osso B, Altamura AC. Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study. Expert Opin Drug Saf. 2012;11(6):893–9.

    Article  CAS  PubMed  Google Scholar 

  41. Michelini S, Cassano GB, Frare F, Perugi G. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry. 1996;29(04):127–34.

    Article  CAS  PubMed  Google Scholar 

  42. Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin. 2004;20:1357–63.

    Article  CAS  PubMed  Google Scholar 

  43. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther. 2001;23(11):1839–54.

    Article  CAS  PubMed  Google Scholar 

  44. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004;65:565–8.

    Article  CAS  PubMed  Google Scholar 

  45. Denys D, de Geus F, Van Megen HJ, Westenberg HG. A doubleblind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65:1040–8.

    Article  CAS  PubMed  Google Scholar 

  46. Doree J-P, Rosiers JD, Lew V, Gendron A, Elie R, Stip E, Valérie Tourjman S. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin. 2007;23(2):333–41.

    Article  CAS  PubMed  Google Scholar 

  47. Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 2003;23(1):15–20.

    Article  CAS  PubMed  Google Scholar 

  48. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005;66(6):736–43.

    Article  CAS  PubMed  Google Scholar 

  49. Patkar AA, Pae C-U. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27 Suppl 1:S29–37.

  50. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient’s clinical profile. CNS Spectr. 2004;9(10 Suppl 11):6.

    PubMed  Google Scholar 

  51. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66(Suppl 5):40–8.

    CAS  PubMed  Google Scholar 

  52. Sharpley AL, Vassallo CM, Cowen PJ. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT 2C receptors in vivo. Biol Psychiatry. 2000;47(5):468–70.

    Article  CAS  PubMed  Google Scholar 

  53. Lorenz RA, Jackson CW, Saitz M. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacother J Human Pharmacol Drug Ther. 2010;30(9):942–51.

    Article  CAS  Google Scholar 

  54. Buoli M, Caldiroli A, Caletti E, Paoli RA, Altamura AC. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opin Pharmacother. 2013;14(2):175–84.

    Article  CAS  PubMed  Google Scholar 

  55. Hoge EA, Worthington JJ, Kaufman RE, Delong HR, Pollack MH, Simon NM. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008;13:522–7.

    PubMed  Google Scholar 

  56. Worthington III JJ, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005;20(1):9–11.

    Article  Google Scholar 

  57. Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry. 2005;57(5):474–9.

    Article  CAS  PubMed  Google Scholar 

  58. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158(5):765–74.

    Article  CAS  PubMed  Google Scholar 

  59. Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21(8):600–20.

    Article  CAS  PubMed  Google Scholar 

  60. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006;21(6):450–5.

    PubMed  Google Scholar 

  61. Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006;67(3):381–5.

    Article  CAS  PubMed  Google Scholar 

  62. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66(10):1321–13235.

    Article  CAS  PubMed  Google Scholar 

  63. Pandina GJ, Canuso CM, Turkoz I, Kujawa M, Mahmoud RA. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull. 2007;40(3):41–57.

    PubMed  Google Scholar 

  64. Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology. 1999;141(3):267–78.

    Article  CAS  PubMed  Google Scholar 

  65. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry. 2002;159(10):1777–9.

    Article  PubMed  Google Scholar 

  66. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002;16(4):365–8.

    Article  CAS  PubMed  Google Scholar 

  67. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59(3):211–5.

    Article  CAS  PubMed  Google Scholar 

  68. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther. 2010;32:S3–20.

    Article  CAS  PubMed  Google Scholar 

  69. Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat. 2008;4(5):937–48.

    CAS  PubMed Central  PubMed  Google Scholar 

  70. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48:1110–9.

    Article  PubMed  Google Scholar 

  71. Menza MA, Dobkin RD, Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol. 2007;27(2):207–10.

    Article  PubMed  Google Scholar 

  72. Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand. 2000;101(6):416–32.

    Article  CAS  PubMed  Google Scholar 

  73. Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13(2):137–77.

    Article  CAS  PubMed  Google Scholar 

  74. Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25:301–10.

    Article  CAS  PubMed  Google Scholar 

  75. Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol. 2005;25(5):497–9.

    Article  PubMed  Google Scholar 

  76. Lohoff FW, Etemad B, Mandos LA, Gallop R, Rickels K. Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol. 2010;30(2):185–9.

    Article  CAS  PubMed  Google Scholar 

  77. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351–60.

    Article  PubMed  Google Scholar 

  78. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev. 2004;(2):CD000967.

  79. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology. 2007;33(10):2303–12.

    Article  PubMed  Google Scholar 

  80. Goldstein J, Christoph G, Grimm S, Liu J, Widzowski D, Brecher M. Quetiapine’s antidepressant properties: direct and indirect pharmacologic actions on norepinephrine and serotonin receptors. Eur Neuropsychopharmacol. 2007;17:S401.

    Article  Google Scholar 

  81. Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord. 2008;22(8):1480–6.

    Article  CAS  PubMed  Google Scholar 

  82. Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington III JJ, Zhang W, Davidson JR, Pollack MH. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology. 2008;197:675–81.

    Article  CAS  PubMed  Google Scholar 

  83. Gabriel A. The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): an open label naturalistic study. La Clinica Terapeutica. 2011;162(2):113.

    CAS  PubMed  Google Scholar 

  84. Altamura AC, Serati M, Buoli M, Dell’Osso B. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol. 2011;26(4):201–5.

    Article  PubMed  Google Scholar 

  85. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010;13:305–20.

    Article  CAS  PubMed  Google Scholar 

  86. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26(1):11–24.

    Article  PubMed  Google Scholar 

  87. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011;31(4):418–28.

    Article  CAS  PubMed  Google Scholar 

  88. Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2012;27(1):40–54.

    Article  PubMed  Google Scholar 

  89. Mezhebovsky I, Magi K, She F, Datto C, Eriksson H. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry. 2013;28(6):615–25.

    Article  PubMed  Google Scholar 

  90. Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, Calabrese JR. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry. 2011;72(8):1063–71.

    Article  PubMed Central  PubMed  Google Scholar 

  91. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults. JAMA. 2011;206(12):1359–69.

    Article  Google Scholar 

  92. Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichler CF. Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007;61(8):1356–70.

    Article  CAS  PubMed  Google Scholar 

  93. Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 2013;62:3232–40.

    Article  CAS  PubMed  Google Scholar 

  94. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–35.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  95. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, O’Reardon JP, Lovett ML, Gladis MM, Brown LL. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):409–16.

    Article  PubMed  Google Scholar 

  96. Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, Gallop R, McGlinchey JB, Markley DK, Gollan JK. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol. 2006;74(4):658.

    Article  PubMed  Google Scholar 

  97. Otto MW, Smits JAJ, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin Psychol Sci Pract. 2005;12(1):72–86.

    Article  Google Scholar 

Download references

Acknowledgments

This material is the result of work supported with resources and the use of facilities of the VISN 4 Mental Illness Research, Education, and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA, and the Ralph H. Johnson Veterans Affairs Medical Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. There were no conflicts of interest in the preparation of this manuscript for Drs. Rachel Hershenberg or Daniel F. Gros. Dr. Olga Brawman-Mintzer received grant support from Forest Laboratories.

Author information

Authors and Affiliations

  1. VISN 4 Mental Illness Research, Education and Clinical Center at Philadelphia VA Medical Center, 3900 Woodland Ave, Philadelphia, PA, 19104, USA

    Rachel Hershenberg

  2. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Rachel Hershenberg

  3. Mental Health Service, Ralph H. Johnson VA Medical Center, Charleston, SC, USA

    Daniel F. Gros & Olga Brawman-Mintzer

  4. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA

    Daniel F. Gros & Olga Brawman-Mintzer

Authors
  1. Rachel Hershenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel F. Gros
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olga Brawman-Mintzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olga Brawman-Mintzer.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hershenberg, R., Gros, D.F. & Brawman-Mintzer, O. Role of Atypical Antipsychotics in the Treatment of Generalized Anxiety Disorder. CNS Drugs 28, 519–533 (2014). https://doi.org/10.1007/s40263-014-0162-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-014-0162-6

Keywords

search

Navigation